Quantifying the patient´s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire.
<h4>Background</h4>The assessment of self-reported outcomes in neuromyelitis optica spectrum disorder (NMOSD) is limited by the lack of validated disease-specific measures. The SymptoMScreen (SyMS) is a patient-reported questionnaire for measuring symptom severity in different domains af...
Guardado en:
Autores principales: | José E Meca-Lallana, Jorge Maurino, Francisco Pérez-Miralles, Lucía Forero, María Sepúlveda, Carmen Calles, María L Martínez-Ginés, Inés González-Suárez, Sabas Boyero, Lucía Romero-Pinel, Ángel P Sempere, Virginia Meca-Lallana, Luis Querol, Lucienne Costa-Frossard, Daniel Prefasi, Rocío Gómez-Ballesteros, Javier Ballesteros |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/189bfa11ecd7489bb2290d28a62384b2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.
por: J E Meca-Lallana, et al.
Publicado: (2021) -
Cytokines and chemokines expression in serum of patients with neuromyelitis optica
por: Ai NP, et al.
Publicado: (2019) -
No association of AQP4 polymorphisms with neuromyelitis optica and multiple sclerosis
por: Yang Ting-Ting, et al.
Publicado: (2016) -
Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder
por: Bo Chen, et al.
Publicado: (2017) -
Paraneoplastic neuromyelitis optica spectrum disorder associated with breast cancer
por: Yuan J, et al.
Publicado: (2019)